Moderna Inc. ($MRNA) Stock Forecast: Down 6.3% Today

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a prominent biotechnology company known for its mRNA technology used in developing vaccines, including the COVID-19 vaccine.

Why is Moderna Inc. going down?

MRNA stock is down 6.3% on Apr 3, 2025 19:07

• Moderna's stock experienced a bearish movement today.
• The bearish sentiment could be attributed to the resignation of a top FDA official, Peter Marks, which has caused uncertainty and concerns within the biotech industry.
• The bullish options trading on Moderna could be unrelated to the stock's movement today, as it might reflect a longer-term positive outlook on the company's prospects.
• Pfizer's recent approval for expanded use of its RSV vaccine in the EU may have also impacted market sentiment towards Moderna, leading to a shift in investor focus towards Pfizer in the short term.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna Options Trading: A Deep Dive into Market Sentiment - Moderna ( NASDAQ:MRNA )

Investors with a lot of money to spend have taken a bearish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

https://www.benzinga.com/insights/options/25/04/44610270/moderna-options-trading-a-deep-dive-into-market-sentiment

PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.

https://www.zacks.com/stock/news/2438778/pfe-secures-eu-nod-for-expanded-use-of-rsv-vaccine-abrysvo

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

https://www.zacks.com/stock/news/2437914/biotech-stocks-fall-after-top-fda-official-quits-over-clash-with-rfk-jr

Moderna's Options Frenzy: What You Need to Know - Moderna ( NASDAQ:MRNA )

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 38 trades. If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 36% ...

https://www.benzinga.com/insights/options/25/03/44569042/modernas-options-frenzy-what-you-need-to-know

Moderna, Novavax Shares Are Tumbling Monday: What's Going On? - Moderna ( NASDAQ:MRNA )

Peter Marks resigns from his role at the FDA's Center for Biologics Evaluation and Research. Pelosi's latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is spotlighting-before it takes off.

https://www.benzinga.com/25/03/44562368/moderna-novavax-shares-are-tumbling-monday-whats-going-on

Trending Today

NEO ($NEO) Crypto Forecast: Up 5.6% Today

Solana ($SOL) Crypto Forecast: Down 7.8% Today

EOS ($EOS) Crypto Forecast: Up 6.4% Today

Wormhole ($W) Crypto Forecast: Up 13.1% Today

Toncoin ($TON) Crypto Forecast: Down 10.3% Today

Copper ($COPPER) Commodity Forecast: Down 5.8% Today

Pepe ($PEPE) Crypto Forecast: Down 17.8% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.9% Today

XRP ($XRP) Crypto Forecast: Down 7.1% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.4% Today

Moderna Inc. Price History

02.03.2025 - MRNA Stock was down 7.4%

• The decline in Moderna's stock price aligns with a broader trend in biotech stocks following the departure of a key FDA official, Peter Marks, over disagreements with the new HHS Secretary. This event has sparked apprehensions regarding regulatory hurdles and leadership stability in the biotech sector.
• Despite optimism evident in options trading, indicating investor expectations of positive outcomes, Moderna's overall market sentiment appears to have been overshadowed by concerns arising from the FDA official's resignation and the resultant regulatory ambiguity.
• Pfizer's recent endorsement for expanding the use of its RSV vaccine in the EU may have further compounded the downward pressure on Moderna's stock as investors evaluate competitive dynamics and potential market implications for Moderna's vaccine portfolio.
• A combination of regulatory uncertainties, market forces, and competitive landscape changes likely contributed to Moderna's bearish performance today, underscoring the vulnerability of biotech stocks to regulatory updates and industry trends.

26.01.2025 - MRNA Stock was down 5.5%

• Despite the prevailing positivity in the vaccine sector, MRNA displayed a bearish trend, possibly linked to profit-taking or concerns about the company's vaccine initiatives.
• The upward movement of other vaccine stocks implies investor confidence in the market prospects tied to the recent coronavirus discovery.
• MRNA's decline could be influenced by internal or market-specific factors rather than industry-wide trends.

20.01.2025 - MRNA Stock was down 5.2%

• Moderna (MRNA) revealed Q4 earnings that fell short of EPS predictions and displayed a decrease in revenue, prompting a downward trend in the market.
• The FDA's decision to pause Moderna's norovirus vaccine trial following a Guillain-Barré syndrome case possibly raised apprehensions among investors, impacting the stock negatively.
• Analysts expressing reservations and issuing downgrades on MRNA stock subsequent to the earnings report might have added to the bearish outlook.
• Despite surpassing revenue projections and confirming guidance, the drop in COVID vaccine sales could have also influenced the stock's decline.

01.03.2025 - MRNA Stock was up 5.5%

• Moderna's stock experienced a strong bullish movement today, likely influenced by the following factors:
• The bullish stance taken by investors in Moderna's options market, with a majority opening trades with bullish expectations.
• The resignation of FDA official Peter Marks, which could potentially lead to changes in regulatory dynamics that investors perceive as favorable for Moderna.
• The overall positive sentiment towards biotech stocks despite the resignation, indicating confidence in the sector's future prospects.
• The uncertainty caused by the Trump administration's reported plans to reduce financial support for vaccine efforts, which could indirectly benefit Moderna as a leading vaccine developer.

26.02.2025 - MRNA Stock was down 6.1%

• The bearish movement in Moderna's stock could be attributed to the Trump administration's plans to cut financial support for vaccine alliance Gavi and scale back efforts to combat malaria.
• Investors may be concerned about the potential impact of reduced government support on Moderna's future vaccine development and sales.
• This development could be seen as a negative catalyst for Moderna's stock price, leading to a bearish market movement as investors react to the uncertainty surrounding the company's future prospects in vaccine development.

03.03.2025 - MRNA Stock was down 6.3%

• Moderna's stock experienced a bearish movement today.
• The bearish sentiment could be attributed to the resignation of a top FDA official, Peter Marks, which has caused uncertainty and concerns within the biotech industry.
• The bullish options trading on Moderna could be unrelated to the stock's movement today, as it might reflect a longer-term positive outlook on the company's prospects.
• Pfizer's recent approval for expanded use of its RSV vaccine in the EU may have also impacted market sentiment towards Moderna, leading to a shift in investor focus towards Pfizer in the short term.

27.01.2025 - MRNA Stock was down 5.5%

• The potential reconsideration of a substantial contract for a bird flu vaccine by a previous administration may have triggered concerns among investors, impacting Moderna's stock negatively.
• Despite this, the bullish outlook from investors with significant funds shows sustained belief in Moderna's future potential, implying the current decline might be temporary.
• The increased interest in vaccine stocks, including Moderna, following reports of a new coronavirus in China underscores the market's sensitivity to disease outbreaks, affecting companies specializing in vaccine research.

06.02.2025 - MRNA Stock was up 7.6%

• Company insiders purchasing shares valued at $6 million may indicate confidence in the company's future, leading to increased investor optimism and driving the stock price up.
• Unusual options activity, with a majority of investors entering trades with bullish expectations, added to positive sentiment around Moderna, contributing to the stock's strong upward movement.
• The blend of insider buying and bullish options activity likely triggered a domino effect, attracting more investors to participate in the upward trend and propelling MRNA stock to surge by 16% in a single day.

11.02.2025 - MRNA Stock was down 8.2%

• Moderna's stock experienced a notable decline today despite recent favorable developments, including the CEO's share purchase and company insiders buying shares totaling $6 million.
• The decrease in stock value could be linked to investors taking profits following a substantial rise in the stock price subsequent to the positive news.
• Various factors, such as industry-specific influences or broader market conditions, may have influenced market participants' decisions, resulting in the stock's downward trajectory.
• Traders are advised to attentively track both company-specific updates and general market trends to make well-informed trading choices with Moderna's stock.

18.01.2025 - MRNA Stock was up 6.6%

• Moderna's (MRNA) stock displayed a significant uptrend during the last trading session.
• Despite reservations voiced by analysts and a decrease in ratings, the company's Q4 financial performance surpassed expectations, including higher revenues, and restated its total revenue projections for 2025.
• The reduction in COVID vaccine sales was counterbalanced by the revenue outperformance. However, a loss was reported due to the downsizing of manufacturing operations, instigating uncertainty in the market.
• Emphasis seems to be placed on the favorable earnings and revenue outcomes rather than the drop in the COVID business, fueling the upward momentum in the stock price.

18.01.2025 - MRNA Stock was up 6.2%

• Moderna reported Q4 earnings and revenues that beat expectations, despite a decline in COVID vaccine sales. This positive financial performance likely contributed to the bullish movement in the stock.
• Despite scaling down manufacturing and facing growing pains, Moderna's ability to surpass revenue estimates showcased its resilience and potential for future growth.
• The downgrade by a top Wall Street analyst for another company, Hims & Hers Health, may have shifted investor focus towards Moderna, leading to increased buying activity and driving the stock price higher.
• Overall, Moderna's strong financial results and ongoing efforts to launch new products seem to have overshadowed any concerns about its COVID business decline, fueling investor optimism and driving the bullish movement in the stock.

28.01.2025 - MRNA Stock was down 6.0%

• Unusual bullish options activity was detected for Moderna, indicating positive sentiment among investors.
• The reconsideration of a $590 million funding contract for a bird flu vaccine by officials may have raised uncertainty and impacted the stock negatively.
• Despite the bullish options trends, the news of potential funding withdrawal and a new coronavirus discovery in China affecting vaccine stocks likely contributed to Moderna's bearish movement.
• The overall market sentiment towards vaccine stocks seems to be mixed, with both positive and negative factors influencing Moderna's performance today.